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BACKGROUND: Epithelial and stromal cells play an important role in the development of colorectal cancer (CRC). We aimed to
determine the prognostic significance of both epithelial and stromal cell apoptosis in CRC.
METHODS: Total apoptosis was determined by caspase-3 activity measurements in protein homogenates of CRC specimens and
adjacent normal mucosa of 211 CRC patients. Epithelial apoptosis was determined by an ELISA specific for a caspase-3-degraded
cytokeratin 18 product, the M30 antigen. Stromal apoptosis was determined from the ratio between total and epithelial apoptosis.
RESULTS: Epithelial and stromal apoptosis, as well as total apoptosis, were significantly higher in CRC compared with corresponding
adjacent normal mucosa. Low total tumour apoptosis (pmedian caspase-3 activity) was associated with a significantly worse disease
recurrence (hazard ratio (HR), 95% confidence interval (95% CI): 1.77 (1.05–3.01)), independent of clinocopathological parameters.
Epithelial apoptosis was not associated with clinical outcome. In contrast, low stromal apoptosis (pmedian caspase-3/M30) was
found to be an independent prognostic factor for overall survival, disease-free survival and disease recurrence, with HRs (95% CI) of
1.66 (1.17–2.35), 1.62 (1.15–2.29) and 1.69 (1.01–2.85), respectively.
INTERPRETATION: Stromal apoptosis, in contrast to epithelial apoptosis, is an important factor with respect to survival and
disease-recurrence in CRC.
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The classical normal mucosa–adenoma–carcinoma sequence of
colorectal cancer (CRC) is associated with a resistance to apoptosis
(Koornstra et al, 2003). The use of apoptosis indices or
measurements as a prognostic or predictive factor for CRC has
been limited by the reliability of the detection techniques and
time consuming evaluations, and have shown conflicting results
(de Bruin and Medema, 2008). Caspases, or death proteases, are
cysteine proteases that are responsible for the morphological
changes within cells during apoptosis (Kumar, 2007). Caspase-3 is
at the point of convergence of the two main apoptotic pathways
and cleaves most of the cellular substrates in the apoptotic process
(Porter and Janicke, 1999). Measurement of caspase-3 activity is
therefore a major and the most reliable determinant of apoptosis
(Kaufmann et al, 2008). Caspase-3-degraded proteins are also used
to detect apoptosis, for instance by the M30 antibody that detects
an epithelial-specific caspase-3-degraded product of cytokeratin 18
(CK18), that is, CK18-Asp396, and therefore specifically detects
apoptotic epithelial cells (Leers et al, 1999).
In recent years it has become clear that stromal cells within the
tumour, and their interactions with the tumour cells, are important
in the initiation and progression of cancer (Mueller and Fusenig,
2004), illustrated by the prognostic relevance of tumour stromal-
epithelial ratios for CRC patients (Mesker et al, 2007). Apoptosis of
stromal cells might therefore also be of prognostic importance for
the patients. To investigate the prognostic impact of stromal
apoptosis, we determined total cellular apoptosis by caspase-3
activity measurement, and epithelial apoptosis by an ELISA for
caspase-3-degraded CK18 (M30 antigen), in a large series of CRC
specimens. Correction of the total apoptosis for the epithelial
apoptosis (caspase-3/M30) revealed the apoptosis of non-epithelial
cells, that is, stromal apoptosis, which was found to be of major
clinical relevance in the CRC patients.
MATERIALS AND METHODS
Patients
The study population consisted of 211 CRC patients that were
admitted to the Leiden University Medical Center for tumour
resection between December 1983 and September 1991, as
previously described (Langers et al, 2008). Fresh tissue was
collected from the non-irradiated surgical specimen immediately
after resection and attention was paid to collect material from the
non-necrotic mid-central part of the tumour. Normal mucosa
samples were obtained whenever possible at a distance of
approximately 10cm from the tumour. Tissue samples were frozen
and stored at  701C until use. Clinical data and follow-up
information were available for a period of at least 5 years after
surgical intervention. Macroscopic (diameter and localisation of
the tumour) as well as microscopic data were assessed, including
Dukes’ stage and differentiation (and ulceration) grade of the
tumour according to the WHO classification. Colonic cancers were
classified as being proximal or distal to, and including, the splenic
flexure. The study was performed according to the guidelines of
the Medical Ethics Committee of the Leiden University Medical
Center and in compliance with the Helsinki Declaration.
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Frozen tissue specimens were weighed and homogenised on ice for
2min in 1ml Tris-HCl, 0.1% Tween 80, pH 7.5 per 60mg tissue
using a Potter device (B Braun, Germany), and centrifuged twice at
8000g for 2.5min at 41C, as described before (Langers et al, 2008).
Protein content was measured according to Lowry et al. (1951)
and standardised by bovine serum albumin (BSA).
Caspase-3 activity measurement
For measurement of caspase-3 enzymatic activity, a colorimetric
assay was used as described before (de Heer et al, 2007). Samples
were incubated with a saturating concentration of 25mM specific
enzyme substrate Ac-Aps-Glu-Val-Asp-AMC (Ac-DEVD-AMC;
Bachem, Heidelberg, Germany) in a total of 100ml 100mM HEPES
buffer, pH 7.25, containing 10% (w/v) sucrose, 0.1% (v/v) Nonidet-
P40 and 10mM dithiothreitol. During incubation at 371C,
fluorescent AMC release by active caspase-3 was monitored at an
excitation of 360nm and an emission of 460nm using a Fluostar
Optima plate reader (BMG Labtech GMBH, Offenburg, Germany).
Calibration curves were constructed using free AMC. Caspase-3
activity was indicated in pmol AMCmin
 1mg
 1 protein. The
intra- and interassay variabilities of the caspase-3 activity assay
were between 5 and 15%.
M30 and CK18 antigen level detection
M30 antigen and total CK18 antigen levels were detected by M30
and M65 ELISAs, according to the manufacturer’s protocol (Peviva
BV, Bromma, Sweden), and expressed as antigen units per mg
protein (Umg
 1). Both ELISAs had intra- and interassay
variabilities o10%, in line with the manufacturer’s specifications.
Western blotting for caspase-3
Tumour protein samples were separated on a 12% polyacrylamide
SDS gel and blotted to a nitrocellulose membrane (Whatman,
Dassel, Germany). After blocking with 2.5% milk powder
(Bio-Rad Laboratories, Hercules, CA, USA) in 0.05% Tween 20
in phosphate-buffered saline (PBST) for 2h at room temperature
(RT) blots were subsequently incubated overnight at 41C with
a rabbit-anti-total-caspase-3 antibody (1:500; Cell Signaling
Technology, Danvers, MA, USA) in 0.5% BSA/PBST and Horse-
radish-peroxidase (HRP)-labelled mouse-anti-rabbit secondary
antibody (1:1000; Dako, Glostrup, Denmark) for 2h at RT. The
signal was developed with Supersignal West Pico Chemilumines-
cent Substrate (Pierce, Rockford, IL, USA), and detected by an
LCD camera (Bio-Rad).
Immunohistochemistry for active caspase-3, M30 antigen
and cytokeratin
Paraffin tissue sections (5mm) were deparaffinised, blocked in
0.3% H2O2 in methanol for 30min at RT and rehydrated through
graded ethanol to phosphate-buffered saline (PBS). Antigen
retrieval was performed by boiling the slides in 10mM citrate
buffer (pH 6.0) for 10min in a microwave oven. After cooling
down to RT and rinsing with PBS for three times the slides were
blocked with 5% goat serum (Dako) in 1% BSA in PBS for 20min
at RT. Afterwards the sections were incubated with the primary
antibody in 1% BSA/PBS overnight at 41C: mouse-anti-pan-
cytokeratin (1:5000, clone C11; Santa Cruz Biotechnologies, Santa
Cruz, CA, USA), mouse M30 Cytodeath antibody (1:400; Roche
Applied Science, Penzberg, Germany) and rabbit-anti-active-
caspase-3 (1:200; Cell Signaling Technology). After washing with
PBS, the slides were incubated with biotinylated goat-anti-mouse
or goat-anti-rabbit secondary antibodies (both 1:200; Dako) in 1%
BSA/PBS for 45min. After thorough washing with PBS, the slides
were incubated with streptavidin–avidin–biotin complex/HRP
(Dako) for 45min at RT. The signal was developed with 0.015%
H2O2 (Merck, Darmstadt, Germany) in 0.05% diaminobenzidine-
tetrahydrochloride (Sigma, Zwijndrecht, The Netherlands) in 0.01 M
Tris-HCL pH 7.6 for 10min resulting in a brown staining product.
Sections were counterstained with Mayers’ haematoxylin (Merck),
dehydrated and mounted in entallan (Merck). Slides without primary
antibody incubations were included as negative controls. Photo-
micrographs of representative sections were taken with a Nikon
Elipse E800 microscope equipped with a Nikon DXM 200 camera.
Statistical analysis
Statistical analysis was performed with Statistical Package for
Social Sciences (SPSS) statistical software (version 12.0 for
Windows; SPSS Inc., Chicago, IL, USA). Wilcoxon signed rank
and Spearman’s rho tests were used to compare paired observa-
tions that did not follow a normal distribution. Kruskall–Wallis
and Mann–Whitney U-tests were used to compare two or more
groups that do not follow a normal distribution. The entry data for
survival analysis were the time of surgery for the primary tumour.
Biomarker expressions were dichotomised and overall survival,
disease recurrence and disease-free survival were evaluated using
Kaplan–Meier methodology with death, local and distant recur-
rence, or both, as events, including log-rank tests. Univariate Cox
proportional hazard models were used to explore the association
of markers with clinical outcome. Variables with a Pp0.1 in the
univariate analyses were subjected to multivariate analyses.
Statistical tests were two-sided and Po0.05 was considered
statistically significant. Graphs were made with Graphpad Prism
(version 4.0; Graphpad Prism Inc., La Jolla, CA, USA) software.
RESULTS
Total, epithelial and stromal apoptosis in colorectal cancer
The caspase-3 activity, M30 antigen and CK18 levels were
determined in colorectal carcinoma tissue of all 211 patients,
whereas due to tissue/homogenate availability these parameters
could only be determined in adjacent normal tissue from
Table 1 Caspase-3 activity, M30 antigen and CK18 levels in tumour tissue and normal adjacent mucosa pairs from 177 colorectal cancer patients
Tissue assessed/parameter Tumour median (IQR) Normal mucosa median (IQR) P value
Caspase-3 activity (pmol AMCmg
 1min
 1) 6.74 (2.96-16.65) 1.28 (0.66-2.20) o0.0001
M30 antigen (Umg
 1) 7.58 (3.13-13.77) 3.20 (1.13-5.66) o0.0001
CK18 (Umg
 1) 209.6 (116.9-273.1) 178.5 (129.6-132.5) 0.008
M30/CK18 100 (epithelial apoptosis) 3.72 (2.52-5.78) 1.83 (0.86-3.16) o0.0001
Caspase-3/M30 (stromal apoptosis) 0.84 (0.44-2.97) 0.38 (0.18-1.18) o0.0001
Epithelial apoptosis (M30/CK18 100) and stromal apoptosis (caspase-3/M30) were calculated from caspase-3, M30 antigen and CK18 levels. P values were determined with
Mann–Whitney U-test. IQR¼interquartile range.
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colorectal tumour tissue samples were significantly higher than
those in the corresponding normal tissue samples in these 177
patients (Table 1).
Immunoblot analysis confirmed that tumours with a high
caspase-3 activity had high protein levels of active caspase-3
compared with low caspase-3 activity tumours (Figure 1A). Overall
there was a weak but significant correlation between tumour
caspase-3 activity and tumour M30 antigen levels, as expected,
because the M30 antigen is generated by active caspase-3
(Figure 1B). Some tumours had really high caspase-3 activity levels,
without high M30 antigen levels, indicating high stromal apoptosis.
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Figure 1 Caspase-3 activity in CRC. CRC specimens with high caspase-3 activity show levels of the active form of caspase-3, whereas low caspase-3
activity CRC specimens only show inactive (pro-) caspase-3 as determined by immunoblotting for total caspase-3 (A). Caspase-3 activity and M30 antigen in
CRC show a weak but significant correlation (B). Some tumours show high caspase-3 activity without high levels of M30 antigen, suggesting stromal
apoptosis. Photomicrographs of immunohistochemical stainings for active caspase-3, M30 and pan-cytokeratin showing tumours with stromal cells
expressing active caspase-3 (C), as represented by Tumour 1 (left panel), and tumours with mainly epithelial cells expressing active caspase-3, correlating
with M30 staining (represented by Tumour 2, right panel). Scale bars¼100mm.
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active caspase-3 was indeed mainly expressed by diverse non-
epithelial cells and were almost M30 antigen-negative (Figure 1C,
represented by Tumour 1), compared with other tumours in which
epithelial cells were expressing most of the active caspase-3 and M30
antigen-positive (represented by tumour 2). Some high power
magnifications of tumour 1 to illustrate the diverse nature of
stromal apoptosis are shown in Supplementary Figure 1. Our
measurements enabled us to further differentiate in cell type origin
of apoptosis by calculating the percentage of apoptotic epithelial
cells through the formula M30/CK18 100 and for stromal
apoptosis through the formula caspase-3/M30. This epithelial as
well as stromal apoptosis was also significantly higher in tumour
tissue compared with corresponding normal tissue (Table 1).
Relation between total, epithelial and stromal apoptosis
and clinical variables
The association between the clinicopathological characteristics of
the 211 colorectal cancer patients and the tissue caspase-3 activity,
as a measure of total apoptosis, is summarised in Table 2. Caspase-
3 activity level in the tumours correlated with gender, tumour
location and Dukes’ stage, that is, significantly higher in females
(P¼0.006) and in tumours located in the proximal colon
(P¼0.02), and decreased with increasing Dukes’ stage (P¼0.01).
Caspase-3 activity in normal mucosa was also found to be higher
in females (P¼0.04) and in the proximal colon (P¼0.04), but did
not correlate with Dukes’ stage.
Tumour M30 antigen levels correlated with grade of differentia-
tion, with well-differentiated tumours having significantly higher
levels (Table 3; P¼0.02). The total amount of epithelial cells (CK18
per mg protein) in the tumour samples correlated with the tumour
diameter, larger tumours having significantly lower amounts of
epithelial cells compared with smaller tumours (P¼0.007).
Epithelial cell apoptosis (M30/CK18 100) was significantly higher
in tumours with ulceration (P¼0.02). Stromal apoptosis (caspase-
3/M30 ratio) was related to gender and tumour location, that is,
significantly higher in females (P¼0.02) and proximal colon
tumours (Po0.001).
Stromal apoptosis predicts overall survival, disease-free
survival and disease recurrence
High caspase-3 activity (4median) in the tumour was associated
with better overall patient survival; median overall survival: 58 vs
34 months (Figure 2A). These patients with high tumour caspase-3
Table 2 Caspase-3 activity in relation to patient and tumour characteristics
Tumour Normal mucosa
Tissue
Patient and tumour
characteristics
No. of patients
(%); total
n¼211
Caspase-3
activity median
(IQR) P value
No. of patients
(%); total
n¼177
Caspase-3
activity median
(IQR) P value
Gender 0.006 0.04
Male 118 (56) 5.93 (1.96–14.55) 102 (58) 1.07 (0.59–2.19)
Female 93 (44) 9.77 (3.89–26.00) 75 (42) 1.40 (0.78–2.21)
Age (median 69 years; range
31–90)
0.48 0.60
oMedian 105 (50) 7.33 (2.76–16.10) 88 (50) 1.23 (0.75–2.05)
XMedian 106 (50) 7.10 (3.39–19.34) 89 (50) 1.37 (0.62–2.38)
Location 0.02 0.04
Right or transverse 73 (35) 10.79 (3.43–47.72) 62 (35) 1.40 (0.80–2.67)
Left colon or sigmoid 72 (34) 5.75 (1.83–16.76) 59 (33) 1.37 (0.70–2.10)
Rectum 66 (31) 5.25 (2.94–14.47) 56 (32) 0.99 (0.52–1.93)
Dukes’ stage 0.01 0.66
A/B 122 (58) 9.00 (3.51–20.35) 106 (60) 1.25 (0.66–2.21)
C 57 (27) 6.19 (2.36–15.27) 45 (25) 1.18 (0.61–2.08)
D 32 (15) 3.80 (1.24–13.16) 26 (15) 1.38 (0.70–2.34)
Tumour + (median 5cm; range
2–12)
0.47 0.98
oMedian 93 (44) 5.98 (3.37–15.64) 79 (45) 1.31 (0.72–2.00)
XMedian 118 (56) 8.38 (2.89–19.36) 98 (55) 1.21 (0.63–2.27)
Grade of differentiation
a 0.10 0.36
Poor 25 (12) 8.23 (3.76–14.77) 21 (12) 2.00 (0.75–2.97)
Moderate 143 (68) 13.46 (4.02–27.33) 122 (69) 1.25 (0.64–2.14)
Well 40 (19) 7.01 (3.79–40.51) 31 (18) 1.28 (0.59–2.19)
WHO classification
a 0.29 0.31
Adenocarcinoma 157 (75) 7.65 (3.36–17.60) 137 (77) 1.23 (0.64–2.09)
Mucinous carcinoma 52 (25) 6.03 (1.75–15.92) 39 (22) 1.39 (0.72–2.62)
Ulceration
a 0.82 0.59
No 48 (27) 6.73 (3.23–25.65) 44 (25) 1.25 (0.74–2.26)
Yes 139 (73) 7.33 (2.94–16.59) 118 (66) 1.30 (0.62–2.17)
P values were calculated with Kruskall–Wallis and Mann–Whitney U-tests, and P valuesp0.05 were considered statistically significant, shown in bold. IQR¼interquartile range.
aSome values were missing.
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survival with a median disease-free survival of 47.5 vs 27 months
for patients with low tumour caspase-3 activity (pmedian;
Figure 2B). Low tumour caspase-3 activity (pmedian) was also
accompanied by a shorter time to recurrence compared to patients
with a high tumour caspase-3 activity (Figure 2C), with 5-year
recurrence rates of 46.1% and 30.3%, respectively. Caspase-3
activity in the normal adjacent mucosa was not associated with
overall survival, disease-free survival or disease recurrence of the
patients (not shown).
Tumour M30 antigen, CK18 or M30/CK18 100 levels did not
show any relation with disease-free survival (Figure 2D, E and F),
overall survival or disease recurrence (not shown). In contrast, the
caspase-3/M30 ratio of the tumours correlated very strongly with
the disease-free survival of the patients (Figure 2G), with a high
ratio (4median) having a significantly better median disease-free
survival of 45 vs 26.5 months for the patients with tumours with a
low ratio.
To underline the importance of stromal apoptosis to the clinical
outcome of the CRC patients, we divided our patient population in
four groups based on median tumour M30 antigen and median
tumour caspase-3 activity levels: (1) low caspase-3/M30 low
(n¼67), (2) low caspase-3/M30 high (n¼39), (3) caspase-3
high/M30 high (n¼68) and (4) caspase-3 high/M30 low (n¼37).
The M30 antigen levels did not have an additive effect in the two
groups with low caspase-3 activity, and therefore groups 1 and 2
were pooled. In the groups with high caspase-3 activity, the
disease-free survival was found to be the best for patients with a
high tumour caspase-3 activity and low M30 antigen level
(Figure 2H; group 4 vs groups 1 and 2, log-rank value: 5.68,
P¼0.02), which strengthened our notion that stromal apoptosis in
the tumour is an important prognostic factor for the patients’
disease-free survival.
The estimates of relative risk of the evaluated parameters to
disease outcome, as calculated by hazard ratios in the univariate
Cox regression analysis, are shown in Table 4. The clinicopatho-
logical factors that were significantly associated with worse
outcome were found to be old age and advanced Dukes’ stage, as
expected. With regard to the apoptosis parameters, a low total
(caspase-3 activity) or low stromal (caspase-3/M30) apoptosis were
consistently found to be associated with a worse overall and
disease-free survival as well as with a higher risk of recurrence.
Adjustment of the apoptosis parameters to the most relevant
clinicopathological parameters, that is, gender, age, Dukes’ stage,
tumour localisation and tumour diameter in the multivariate Cox
proportional hazards analysis, identified stromal apoptosis as an
independent prognostic factor for overall survival, disease-free
survival and disease recurrence. In contrast, total apoptosis
was found to be an independent prognostic factor for disease
recurrence only (Table 4).
Table 3 Tumour M30 antigen, CK18, M30/CK18 x 100 and caspase-3/M30 ratio in relation to patient and tumour characteristics of colorectal cancer
patients
Parameter/patient and
tumour characteristics
Tumour M30
(Umg
 1);
median (IQR) P value
Tumour CK18
(Umg
 1);
median (IQR) P value
Tumour M30/
CK18 100;
median (IQR) P value
Tumour
caspase-3/M30;
median (IQR) P value
Gender 0.34 0.72 0.53 0.02
Male 8.7 (3.6–15.2) 218.7 (128.6–287.9) 3.9 (2.5–6.7) 0.8 (0.3–2.2)
Female 8.1 (3.2–13.7) 204.8 (124.4–291.8) 3.8 (2.3–5.4) 1.0 (0.5–4.9)
Age 0.94 0.38 0.22 0.43
oMedian 8.7 (3.1–15.2) 224.5 (127.6–296.7) 3.6 (2.2–5.9) 0.8 (0.4–4.0)
XMedian 8.4 (3.9–13.8) 214.6 (125–7–263.7) 4.0 (2.9–5.8) 0.9 (0.4–2.9)
Location 0.06 0.17 0.24 o0.001
Right or transverse 6.8 (2.4–12.7) 189.0 (124.8–257.8) 3.6 (1.8–6.3) 2.1 (0.6–7.6)
Left colon/sigmoid 9.2 (3.5–15.5) 208.6 (113.4–288.8) 3.8 (2.7–5.8) 0.8 (0.4–2.2)
Rectum 9.4 (5.9–15.3) 224.6 (164.9–302.4) 3.9 (3.0–5.7) 0.7 (0.3–1.1)
Dukes’ stage 0.54 0.93 0.38 0.21
A/B 8.6 (3.5–15.2) 215.3 (128.7–292.5) 3.8 (2.7–6.6) 0.9 (0.5–3.2)
C 8.8 (3.4–14.9) 224.5 (137.9–278.6) 4.0 (2.5–5.7) 0.8 (0.3–2.8)
D 6.8 (2.8–12.6) 206.2 (104.0–291.2) 3.5 (2.1–5.0) 0.5 (0.3–2.3)
Tumour diameter 0.14 0.007 0.42 0.15
oMedian 9.6 (3.7–15.2) 234.8 (153.6–316.0) 3.7 (2.3–5.8) 0.7 (0.4–2.4)
XMedian 7.2 (3.2–13.7) 192.0 (116.0–262.0) 3.8 (2.7–6.9) 0.9 (0.4–3.3)
Grade of differentiation 0.02 0.10 0.17 0.35
Poor 7.4 (1.6–15.4) 197.1 (78.1–274.8) 4.9 (2.6–7.0) 1.4 (0.4–5.0)
Moderate 8.0 (3.2–13.8) 215.1 (122.9–275.1) 3.6 (2.3–5.4) 0.9 (0.4–3.0)
Well 11.8(5.6–19.8) 226.7 (150.0–400.0) 4.0 (2.9–8.6) 0.8 (0.4–1.8)
WHO classification 0.35 0.74 0.29 0.79
Adenocarcinoma 8.7 (3.6–15.0) 214.5 (130.7–291.4) 3.8 (2.7–6.4) 0.8 (0.4–2.9)
Mucinous carcinoma 7.7 (2.8–14.2) 223.6 (116.6–262.6) 3.7 (2.1–5.4) 0.9 (0.3–3.1)
Ulceration 0.36 0.85 0.02 0.07
No 5.5 (2.6–15.2) 210.4 (126.0–322.7) 3.1 (2.0–5.1) 1.3 (0.6–4.2)
Yes 8.6 (3.5–14.1) 217.4 (129.2–280.0) 3.8 (2.8–5.8) 0.8 (0.4–2.9)
P values were calculated with Kruskall–Wallis and Mann–Whitney U-tests, and Pp0.05 were considered statistically significant, shown in bold. IQR¼interquartile range.
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sDISCUSSION
This study shows that stromal apoptosis in CRC is a major
determinant for the clinical outcome of patients. The stromal
compartment of colorectal carcinomas is populated by a wide
variety of cell types, such as immune cells, fibroblasts, myofibro-
blasts and endothelial cells. Recent studies have demonstrated that
genetic instability of both the stromal and epithelial compart-
ment contributes to the genesis of CRC (Ishiguro et al, 2006).
Important signalling pathways that are frequently disrupted in
CRC, such as the transforming growth factor (TGF)-b (Naber et al,
2008), bone morphogenic protein (BMP; Hardwick et al, 2008) and
Wnt pathway (Macheda and Stacker, 2008), play a role in both
the cancer-associated stromal and epithelial compartment in the
development of CRC. The presence of fibroblasts (Ngan et al,
2007), myofibroblasts (Tsujino et al, 2007) and endothelial cells
(Baeten et al, 2006) in the cancer-associated stroma contributes to
progression of CRC and a worse patient prognosis. Also, the
expression of other proteins in the cancer-associated stroma, that
is, hypoxia regulated proteins (Cleven et al, 2007), matrix
degrading proteases (Hilska et al, 2007) and cyclooxygenase-2
(Sonoshita et al, 2002; Adegboyega et al, 2004), is correlated to
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Figure 2 Clinical outcome of CRC patients in relation to caspase-3 activity, M30 and CK18 antigen levels. Kaplan–Meier overall survival (A), disease-free
survival (B, D–H) and recurrence (C) curves of all CRC patients (n¼211), groups divided on median tumour caspase-3 activity (A–C), median M30
antigen (D), median CK18 (E), median M30/CK18 100 (F), median caspase-3/M30 (G) and both median caspase-3 and median M30 levels (H). Log-rank
test were used to compare the curves.
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cancer-associated stroma in CRC is most simply illustrated by the
reported prognostic significance of the tumour-stroma ratio in
CRC (Mesker et al, 2007). The cancer-associated stromal cells, and
their interaction with the epithelial tumour cells, are therefore
speculated to be important targets for future therapy (Mueller and
Fusenig, 2004).
Programmed cell death, that is, apoptosis, is an important
mechanism to maintain tissue homoeostasis. Defects in the two
main apoptotic pathways, the extrinsic and intrinsic pathways,
Table 4 Univariate and multivariate Cox regression hazard analysis for overall and disease-free survival, and risk of recurrence including the
clinicopathological factors of all patients (n¼211) and the specified apoptosis assessments
Outcome/patient and tumour
characteristics
Overall survival
HR (95 % CI) P value
Disease-free
survival; HR (95
%C I ) P value
Risk of
recurrence; HR
(95 % CI) P value
Univariate analysis
Gender
Female 1 (ref) 0.08 1 (ref) 0.03 1 (ref) 0.16
Male 1.35 (0.96–1.89) 1.44 (1.03–2.02) 1.43 (0.87–2.36)
Age (median 69 years, range 31–90)
oMedian 1 (ref) o0.001 1 (ref) 0.001 1 (ref) 0.26
XMedian 1.83 (1.31–2.58) 1.78 (1.27–2.49) 1.33 (0.81–2.17)
Location
Right or transverse 1 (ref) 1 (ref) 1 (ref)
Left colon or sigmoid 1.07 (0.72–1.57) 0.75 1.12 (0.76–1.64) 0.58 1.13 (0.65–1.97) 0.66
Rectum 0.69 (0.45–1.05) 0.08 0.70 (0.46–1.06) 0.09 0.80 (0.40–1.58) 0.52
Dukes’ stage
A/B 1 (ref) 1 (ref) 1 (ref)
C 1.93 (1.31–2.84) 0.001 2.00 (1.36-2.93) o 0.001 3.35 (2.04–5.52) o 0.001
D 7.54 (4.69–12.12) o 0.001 5.53 (3.50–8.73) o 0.001 0.31 (0.04–2.28) 0.25
Tumour + (median 5cm, range 2–12)
oMedian 1 (ref) 0.14 1 (ref) 0.09 1 (ref) 0.12
XMedian 1.29 (0.92–1.81) 1.34 (0.96–1.87) 1.50 (0.90–2.50)
Grade of differentiation
Poor 1 (ref) 0.16 1 (ref) 0.16 1 (ref) 0.23
Moderate/well 1.42 (0.87–2.34) 1.30 (0.90–1.89) 0.62 (0.28–1.36)
WHO classification
Adenocarcinoma 1 (ref) 0.94 1 (ref) 0.93 1 (ref) 0.73
Mucinous carcinoma 0.99 (0.67–1.45) 0.98 (0.67–1.44) 0.90 (0.51–1.61)
Ulceration
No 1 (ref) 0.26 1 (ref) 0.45 1 (ref) 0.12
Yes 1.28 (0.83–1.98) 1.18 (0.77–1.80) 1.57 (0.82–3.02)
Tumour caspase-3 activity
4Median 1 (ref) 0.04 1 (ref) 0.02 1 (ref) 0.04
pMedian 1.41 (1.01–1.97) 1.48 (1.07–2.06) 1.68 (1.02–2.78)
Tumour M30 level
4Median 1 (ref) 0.71 1 (ref) 0.90 1 (ref) 0.38
pMedian 0.94 (0.67–1.31) 0.94 (0.71–1.36) 0.80 (0.49–1.31)
Tumour CK18 level
4Median 1 (ref) 0.99 1 (ref) 0.82 1 (ref) 0.67
pMedian 1.00 (0.72–1.39) 1.04 (0.75–1.44) 0.90 (0.55–1.47)
Tumour M30/CK18 100 level
4Median 1 (ref) 0.52 1 (ref) 0.57 1 (ref) 0.83
pMedian 0.90 (0.64–1.25) 0.91 (0.65–1.26) 0.95 (0.58–1.55)
Tumour caspase-3/M30 level
4Median 1 (ref) 0.02 1 (ref) 0.02 1 (ref) 0.05
pMedian 1.51(1.08–2.11) 1.48 (1.06–2.06) 1.64 (1.00–2.70)
Multivariate analysis
Low tumour caspase-3 activity 1.25 (0.87–1.80) 0.22 1.32 (0.92–1.88) 0.13 1.77 (1.05–3.01) 0.03
Low tumour caspase-3/M30 level 1.66 (1.17–2.35) 0.004 1.62 (1.15–2.29) 0.006 1.69 (1.01–2.85) 0.04
In the multivariate analyses the apoptosis parameters were adjusted for gender, age, Dukes’ stage, tumour diameter and tumour location. Pp0.05 were considered statistically
significant, shown in bold. CI¼confidence interval.
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Epithelial apoptosis in CRC has been widely studied but still the
significance for the prognosis of CRC patients, as well as the
significance for the response to treatment such as chemotherapy, is
unclear (Koornstra et al, 2003; de Bruin and Medema, 2008). As
apoptosis in the cancer-associated stroma could also play an
important role, and its induction could be relevant for treatment
response, we investigated the contribution of stromal apoptosis, as
well as epithelial apoptosis in the clinical outcome of CRC.
We showed that both epithelial and stromal apoptosis, as well as
total apoptosis, were significantly higher in non-irradiated CRC
than in normal adjacent mucosa, as found in other studies
(Leonardos et al, 1999; Jonges et al, 2001; Koornstra et al, 2003; de
Heer et al, 2007; de Oca et al, 2008). As cancer cells usually have
apoptotic defects and are more difficult to drive into apoptosis
(Igney and Krammer, 2002; Brown and Attardi, 2005), higher levels
of apoptosis in cancer, compared with normal tissue, might seem
to be somewhat unexpected. However, the level of apoptosis and
sensitivity to apoptotic signals are two, although related, different
things. Importantly, in this study, total CRC apoptosis decreased
with increasing Dukes’ stage, whereas no such correlation was
found in adjacent normal mucosa, which indeed indicates that cells
in the tumour become resistant to apoptotic signals during tumour
progression resulting in a decreased caspase-3 activity in more
advanced tumour stages. Moreover, total apoptosis in the tumour
showed a strong association with risk of recurrence and disease-
free survival. Cox multivariate hazards analysis identified low
caspase-3 activity in the tumour as an independent risk factor of
recurrence, with patients with tumour caspase-3 activity below the
median value having a 1.77 times higher relative risk of recurrence,
similar as reported by others for both colon and rectal cancer (de
Heer et al, 2007; de Oca et al, 2008). Caspase-3 activity corrected
for the percentage of epithelial cells, as determined on slides,
showed similar results compared with the uncorrected caspase-3
activity in rectal cancer in the study by de Heer et al (2007), and
therefore the authors concluded that caspase-3 activity is a
prognostic factor for local recurrence in rectal cancer without
the previous knowledge of epithelial-stromal ratios in the tumour.
Correction of caspase-3 activity for the amount of epithelial cells
(measured by CK18 antigen levels), caspase-3/CK18, in this study
indeed showed similar results with respect to clinicopathological
parameters and clinical outcome, as caspase-3 activity alone (not
shown). However, this does not indicate the source of the caspase-
3 activity; it could be that most of the caspase-3 activity is
produced by apoptotic epithelial cells, and the apoptotic stromal
cells could also be an important source. To investigate the source
we determined M30 antigen levels by ELISA in the same CRC
homogenates, as a measurement of epithelial caspase-3 activity/
apoptosis (Leers et al, 1999; Hagg et al, 2002). If apoptotic
epithelial cells were mainly responsible for the caspase-3 activity in
this study, M30 antigen levels should have shown a similar
correlation with patient and tumour characteristics, which was
clearly not the case. Our measurement of epithelial apoptosis,
determined by M30/CK18 100 (%), with median values of 3.72%
for tumour tissue and 1.83% for normal tissue, is very much in line
with epithelial apoptosis found in other studies (Koornstra et al,
2003). M30 antigen levels, either corrected for CK18 or un-
corrected, did not correlate with overall survival, disease-free
survival or disease recurrence, in contrast to caspase-3 activity,
indicating the importance of non-epithelial caspase-3 activity, that
is, stromal apoptosis. This was confirmed by determining caspase-
3/M30 ratios, as stromal apoptosis levels, which even showed a
stronger association with overall survival, disease-free survival or
disease recurrence. Low stromal apoptosis (pmedian caspase-3/
M30) was an independent prognostic factor for overall survival,
disease-free survival and disease recurrence with an HR (95% CI)
of 1.66 (1.17–2.35), 1.62 (1.15–2.29) and 1.69 (1.01–2.85),
respectively.
Epithelial tumour cell apoptosis has been extensively studied in
CRC, but still the relevance of the apoptotic index as a prognostic
factor is a matter of debate (Koornstra et al, 2003; de Bruin and
Medema, 2008). The detection technique is likely to influence the
apoptotic levels, as some detection techniques are really specific
for epithelial apoptotic cells, that is, M30 immunohistochemistry
and M30 ELISA (Leers et al, 1999; Hagg et al, 2002), and others are
(more or less) specific for apoptotic cells in general, that is, TdT-
mediated dUTP-biotin nick end-labeling (TUNEL) (Stadelmann
and Lassmann, 2000; Barrett et al, 2001), active caspase-3
immunohistochemistry or caspase-3 activity measurements
(Kaufmann et al, 2008), and also detect apoptotic stromal cells.
The results presented here, that is, stromal apoptosis as an
important prognostic factor for CRC, suggests that discrepancies
found in the literature might be explained by the different
detection techniques that are used, that is, ‘specific for epithelial
apoptosis’ vs ‘specific for apoptosis in general’.
In conclusion, this study confirms that caspase-3 activity within
tumour tissue is an important denominator of disease recurrence
and patient survival in CRC, with high levels of caspase-3
associated with good outcome. Remarkably, this caspase-3 activity
was found to predominantly reside within the non-epithelial
compartment of the tumours. These observations underline the
importance of stromal cell apoptosis in CRC progression and
identify the cancer-associated stroma as a potential therapeutic
target.
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